Focinvez J Code: J1434

Drug & Product Overview

HCPCS Descriptor Injection, fosaprepitant (focinvez), 1 mg

HCPCS Added Date April 1, 2024

Manufacturer Amneal Pharmaceuticals

Route of Administration Intravenous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection

About Focinvez

Focinvez is a medication aligned to the HCPCS J Code: J1434 for billing, pricing, and reimbursement purposes in the United States. This Antiviral medication is administered via the intravenous route and manufactured by Amneal Pharmaceuticals.

According to CMS Drug Use Information: Fosaprepitant is used with other medications to help prevent nausea and vomiting caused by cancer drug treatment (chemotherapy). Fosaprepitant works by blocking one of the body's natural substances (substance P/neurokinin 1) that causes vomiting. This medication will not treat nausea or vomiting that has already started. Ask your doctor what you should do if you already have nausea or vomiting.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
70121-2631-01	Focinvez	Amneal Pharmaceuticals LLC	150	150 MG / 50 ML

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

Focinvez Pricing & Reimbursement

J1434 Private Payer Reimbursement

$2.65 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q4 2026

Fosaprepitant 505(b)(2) Information:

HCPCS Code	Manufacturer	Active Ingredient	HCPCS Description
J1434	Amneal Pharmaceuticals	Fosaprepitant	Injection, fosaprepitant (focinvez), 1 mg
J1453	Generic Code (Multiple Manufacturers)	Fosaprepitant	Injection, fosaprepitant, 1 mg
J1456	Teva	Fosaprepitant	Injection, fosaprepitant (teva), not therapeutically equivalent to j1453, 1 mg

Focinvez Claims Performance

Claims from Jan 2026 – Aug 2026

Claim Denial Rate 6.24%

Avg. Days to File 8.1days

Avg. Days to Pay 25.8days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore J1434 claims analytics on FocalPoint →

Focinvez CPT Administration Codes

CPT Code	Description
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)

Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

Focinvez Medically Unlikely Edits (MUE)

The most billing units of J1434 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 1 mg.

Practitioner Office & Hospital Outpatient

150 units / day

= 150 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

Focinvez Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin Prevention of delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy (MEC) Prevention of nausea and vomiting associated with highly emetogenic (HEC) or moderately emetogenic (MEC) cancer chemotherapy

Drug Class

Cytochrome P450 2C9 Inducers [MoA]Cytochrome P450 3A4 Inducers [MoA]Cytochrome P450 3A4 Inhibitors [MoA]Neurokinin 1 Antagonists [MoA]Substance P/Neurokinin-1 Receptor Antagonist [EPC]

Frequently Asked Questions

Is there an available Focinvez billing and coding guide?

Billing and coding information for Focinvez can be found through Amneal Biosciences. Visit Here →

Are there any available Focinvez patient assistance programs?

Focinvez patient assistance information can be found through Spes Pharmaceuticals. Visit Here →

Where can I find Cyanokit prescribing information?

Focinvez prescribing information can be found at the link below: Visit Here →

Where can I find Focinvez side effect information?

Our team has not yet identified a source of side effect information for Focinvez.

Does billing Focinvez require JZ/JW wastage modifiers?

CMS does not include Focinvez (J1434) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J1434. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.